Cantor Fitzgerald Brokers Boost Earnings Estimates for TARA

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimates for Protara Therapeutics, now expecting a loss of ($1.40) per share, improved from a previous forecast of ($1.71).
• Protara Therapeutics reported quarterly earnings of ($0.35) per share, exceeding analysts' expectations of ($0.43) by $0.08.
• Institutional investors have significantly increased their stake in Protara, with hedge funds owning 38.13% of the company’s stock, indicating growing interest and confidence in the firm.

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Protara Therapeutics in a report issued on Monday, August 18th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($1.40) for the year, up from their prior forecast of ($1.71). The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. Cantor Fitzgerald also issued estimates for Protara Therapeutics' FY2026 earnings at ($1.50) EPS.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08.

TARA has been the subject of a number of other reports. HC Wainwright reissued a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 28th. Jones Trading raised shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 target price for the company in a research note on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $19.60.

Protara Therapeutics Stock Performance

Shares of TARA remained flat at $3.11 during mid-day trading on Wednesday. 50,421 shares of the stock were exchanged, compared to its average volume of 326,545. The stock's 50-day simple moving average is $3.10 and its 200-day simple moving average is $3.53. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The company has a market cap of $119.98 million, a P/E ratio of -1.92 and a beta of 1.42.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics in the 4th quarter worth $111,000. Bank of America Corp DE lifted its holdings in Protara Therapeutics by 53,013.9% in the 4th quarter. Bank of America Corp DE now owns 194,397 shares of the company's stock worth $1,026,000 after buying an additional 194,031 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Protara Therapeutics in the 4th quarter worth $802,000. Geode Capital Management LLC lifted its holdings in Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock worth $948,000 after buying an additional 9,553 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in Protara Therapeutics by 2,479.2% in the 4th quarter. Millennium Management LLC now owns 371,453 shares of the company's stock worth $1,961,000 after buying an additional 357,051 shares in the last quarter. Institutional investors and hedge funds own 38.13% of the company's stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.